search
Back to results

Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel

Primary Purpose

Ethmoid Sinusitis, Rhinosinusitis

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
AdvaCoat sinus gel
Merogel Injectable
Sponsored by
Carbylan Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ethmoid Sinusitis focused on measuring rhinosinusitis, ethmoid

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients who:

  1. Have bilateral chronic rhinosinusitis confirmed by physical exam, clinical history, and prior radiography
  2. Have bilateral ethmoid sinus disease
  3. Are scheduled for bilateral anterior or total ethmoidectomy

Exclusion Criteria:

  1. Unilateral ethmoid sinus disease
  2. Partial resection of middle turbinates, unilateral or bilateral

Sites / Locations

  • Alabama Nasal & Sinus Center
  • University of California, San Francisco, Dept of Otolaryngology
  • Northwestern University Medical Center, Department of Otolaryngology
  • Cleveland Nasal Sinus & Sleep

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing

Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat

Outcomes

Primary Outcome Measures

Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale
Synechia (adhesion) scale range of 0 = No visible synechia to 3 = Complete scarring between the middle turbinate and lateral nasal wall was used in the assessment.
Number of Participants With Solicited and Recorded Adverse Events
All reported events were coded to a standard set of terms using the MedDRA adverse event dictionary. Adverse events were listed and summarized.

Secondary Outcome Measures

Full Information

First Posted
November 2, 2007
Last Updated
April 22, 2009
Sponsor
Carbylan Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00554190
Brief Title
Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel
Official Title
A Prospective, Multi-Center, Randomized, Controlled, Subject-Blinded Study to Evaluate the Safety and Effectiveness of AdvaCoat Sinus Gel Following Endoscopic Ethmoid Sinus Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Carbylan Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of AdvaCoat® sinus gel, a nasal/sinus dressing, for adhesion prevention following endoscopic ethmoid sinus surgery. Subjects were randomized to receive AdvaCoat applied to the right or left middle meatus tissues and Merogel applied to the middle meatus tissues on the opposite side.
Detailed Description
Chronic rhinosinusitis is a very common condition, affecting 35 million Americans each year. All paranasal sinuses need ventilation to prevent infection and inflammation. Sinus ventilation occurs through the ostia into the nose. When rhinosinusitis occurs, the mucous membranes of the sinuses become swollen, resulting in ostia closure. Functional endoscopic sinus surgery (FESS) is a minimally invasive surgical procedure that opens the sinus ostia. The most common unwanted side effect of the FESS procedure is the formation of adhesions (fibrous bands) in the area of surgery. These bands (adhesions) can prevent proper ventilation and drainage from the paranasal sinuses. Various hyaluronan based biomaterials are now available and in common use to provide a post-surgical nasal dressing which is absorbable, can prevent adhesion formation, and eliminate the pain and tissue abrasion caused by removal of non-absorbable nasal packing. AdvaCoat is a bioresorbable hyaluronan gel that conforms to mucosal surfaces and provides a post-surgical nasal dressing to prevent adhesion formation as tissues heal.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ethmoid Sinusitis, Rhinosinusitis
Keywords
rhinosinusitis, ethmoid

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
29 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
Arm Title
2
Arm Type
Active Comparator
Arm Description
Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
Intervention Type
Device
Intervention Name(s)
AdvaCoat sinus gel
Intervention Description
A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
Intervention Type
Device
Intervention Name(s)
Merogel Injectable
Other Intervention Name(s)
Merogel
Intervention Description
Bioresorbable hyaluronic acid product
Primary Outcome Measure Information:
Title
Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale
Description
Synechia (adhesion) scale range of 0 = No visible synechia to 3 = Complete scarring between the middle turbinate and lateral nasal wall was used in the assessment.
Time Frame
Post-operative through 60 days
Title
Number of Participants With Solicited and Recorded Adverse Events
Description
All reported events were coded to a standard set of terms using the MedDRA adverse event dictionary. Adverse events were listed and summarized.
Time Frame
Post-operative through 60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who: Have bilateral chronic rhinosinusitis confirmed by physical exam, clinical history, and prior radiography Have bilateral ethmoid sinus disease Are scheduled for bilateral anterior or total ethmoidectomy Exclusion Criteria: Unilateral ethmoid sinus disease Partial resection of middle turbinates, unilateral or bilateral
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew N. Goldberg, MD
Organizational Affiliation
University of California, San Francisco, Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alabama Nasal & Sinus Center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35242
Country
United States
Facility Name
University of California, San Francisco, Dept of Otolaryngology
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Northwestern University Medical Center, Department of Otolaryngology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Cleveland Nasal Sinus & Sleep
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44125
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel

We'll reach out to this number within 24 hrs